20 July 2023
20 July 2023
The biotech announced its employee cuts as part of a strategic update partly caused by the termination of its AstraZeneca collaboration.
Ahead of APEC’s "Rare disease vision 2025" deadline, Asian countries are working at different speeds towards improving drug market access.
The restructuring plans are expected to reduce the company’s operational costs by $40m annually.
Palovarotene has obtained authorisation for usage in Canada and provisional approval in the UAE.
ARX517 is being evaluated in a Phase I/II APEX-01 trial in mCRPC patients.
B. pseudomallei is resistant to many antibiotics and, without treatment, can be lethal to those infected.
The agreement covers licensing rights in North America for Duchenne muscular dystrophy and other future indications.
Additional clinical data showed improved clinical and anatomical outcomes in DME and wet AMD.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
